Titre:
  • Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Auteur:Loi, Sherene; Sirtaine, Nicolas; Piette, Fanny; Salgado, Roberto; Viale, Giuseppe; Van Eenoo, Françoise; Rouas, Ghizlane; Francis, Prudence; Crown, John P A; Hitre, Erika; Azambuja, Evandro; Quinaux, Emmanuel; Di Leo, Angelo; Michiels, Stefan; Piccart-Gebhart, Martine; Sotiriou, Christos
Informations sur la publication:Journal of clinical oncology, 31, 7, page (860-867)
Statut de publication:Publié, 2013-03
Sujet CREF:Cancérologie
Sciences biomédicales
MeSH keywords:Adult
Aged
Antibiotics, Antineoplastic -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- therapeutic use
Breast Neoplasms -- chemistry -- drug therapy -- immunology -- pathology
Chemotherapy, Adjuvant
Cyclophosphamide -- administration & dosage
Disease-Free Survival
Doxorubicin -- administration & dosage
Female
Fluorouracil -- administration & dosage
Humans
Kaplan-Meier Estimate
Lymph Nodes -- pathology
Lymphatic Metastasis
Lymphocytes, Tumor-Infiltrating
Methotrexate -- administration & dosage
Middle Aged
Predictive Value of Tests
Prognosis
Receptor, erbB-2 -- analysis
Receptors, Estrogen -- analysis
Taxoids -- administration & dosage
Treatment Outcome
Tumor Markers, Biological -- analysis
Note générale:Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2011.41.0902
info:pii/JCO.2011.41.0902
info:scp/84875722651
info:pmid/23341518